Akili announces fda authorization of endeavorotc, the first fda clearance of a digital treatment for adults with adhd through a video game

Boston--(business wire)--akili, inc. (nasdaq: akli), a leading digital therapeutics company, today announced u.s. food and drug administration (fda) clearance of endeavorotcⓇ (akl-t01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (adhd). delivered through an engaging video game experience, endeavorotc is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type adhd, who.
AKLI Ratings Summary
AKLI Quant Ranking